About ruxolitinib phosphate
JAK1/JAK2 inhibitor
Used for
- Myelofibrosis
- Polycythaemia vera when hydroxyurea is unsuitable or ineffective
- Graft-versus-host disease in certain patients
Usual adult dose
Myelofibrosis: usually 5–25 mg twice daily, adjusted to blood counts. Polycythaemia vera: usually 10 mg twice daily. Graft-versus-host disease: usually 5–10 mg twice daily.
Usual dose in children
Graft-versus-host disease: dosing is based on body weight and blood counts; specialist supervision is required.
Common side effects
- Low blood cell counts, including anaemia and low platelets
- Bruising or bleeding
- Infections, including shingles
- Dizziness or headache
Important warnings
- Can cause serious infections; tuberculosis and hepatitis screening may be needed.
- Blood counts require regular monitoring; dose changes may be necessary.
- Stopping suddenly can cause symptoms to worsen; tapering may be needed.
- May increase cholesterol and the risk of some skin cancers.
Pregnancy
May harm an unborn baby. Pregnancy is generally avoided during treatment; reliable contraception is recommended.
Breastfeeding
Breastfeeding is not recommended during treatment and for a period after the last dose.
Interactions
- Strong CYP3A4 inhibitors, such as clarithromycin, can raise ruxolitinib levels.
- Fluconazole can raise levels; dose adjustment may be needed.
- Rifampicin and other strong enzyme inducers can lower levels.
- Other medicines that suppress the immune system may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.